MX2020004076A - Composiciones oftalmicas estabilizadas de omega 3. - Google Patents

Composiciones oftalmicas estabilizadas de omega 3.

Info

Publication number
MX2020004076A
MX2020004076A MX2020004076A MX2020004076A MX2020004076A MX 2020004076 A MX2020004076 A MX 2020004076A MX 2020004076 A MX2020004076 A MX 2020004076A MX 2020004076 A MX2020004076 A MX 2020004076A MX 2020004076 A MX2020004076 A MX 2020004076A
Authority
MX
Mexico
Prior art keywords
ophthalmic compositions
omega
stabilized ophthalmic
stabilized
keratoconjunctivitis
Prior art date
Application number
MX2020004076A
Other languages
English (en)
Inventor
Anurandha V Gore
Jaya Giyanani
Sukhon Likitlersuang
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54784036&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2020004076(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of MX2020004076A publication Critical patent/MX2020004076A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/085—Ethers or acetals having an ether linkage to aromatic ring nuclear carbon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/55—Linaceae (Flax family), e.g. Linum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Se proporcionan composiciones oftálmicas estabilizadas que contienen aceites omega 3, que son útiles como lágrimas artificiales y como composiciones oftálmicas para diagnosticar, tratar o prevenir la queratoconjuntivitis o síndrome del ojo seco en un ser humano u otro mamífero.
MX2020004076A 2014-11-25 2017-05-17 Composiciones oftalmicas estabilizadas de omega 3. MX2020004076A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201462083980P 2014-11-25 2014-11-25

Publications (1)

Publication Number Publication Date
MX2020004076A true MX2020004076A (es) 2020-07-29

Family

ID=54784036

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017006474A MX372988B (es) 2014-11-25 2015-11-23 Composiciones oftalmicas estabilizadas de omega 3.
MX2020004076A MX2020004076A (es) 2014-11-25 2017-05-17 Composiciones oftalmicas estabilizadas de omega 3.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MX2017006474A MX372988B (es) 2014-11-25 2015-11-23 Composiciones oftalmicas estabilizadas de omega 3.

Country Status (17)

Country Link
US (5) US10279005B2 (es)
EP (1) EP3223794A1 (es)
JP (1) JP6768653B2 (es)
KR (1) KR102487299B1 (es)
CN (1) CN107106483B (es)
AU (1) AU2015353701B2 (es)
CA (1) CA2967413C (es)
CL (1) CL2017001301A1 (es)
CO (1) CO2017005624A2 (es)
IL (1) IL252161B (es)
MX (2) MX372988B (es)
NZ (1) NZ732058A (es)
PH (1) PH12017500922A1 (es)
RU (1) RU2697844C9 (es)
SG (1) SG11201704167PA (es)
UA (1) UA121399C2 (es)
WO (1) WO2016085885A1 (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11903986B2 (en) 2016-08-19 2024-02-20 Akrivista Llc Methods of diagnosing and treating dry eye syndrome and compositions for treating a human eye
CN114376961A (zh) 2017-08-18 2022-04-22 阿克里维斯塔有限责任公司 诊断和治疗干眼综合症的方法和用于治疗人类眼睛的组合物
WO2019045994A1 (en) * 2017-08-27 2019-03-07 Rhodes Technologies PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OPHTHALMIC CONDITIONS
CN109364153A (zh) * 2018-11-30 2019-02-22 河南科高中标检测技术有限公司 一种缓解和治疗电子辐射类视疲劳的组合物、制备方法及其应用
AR118828A1 (es) 2019-05-02 2021-11-03 Tearclear Corp Extracción de conservante de colirios
MX2022007389A (es) * 2019-12-19 2022-08-10 Tearclear Corp Remocion del conservante de las gotas para los ojos.
KR102365009B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
KR102365008B1 (ko) * 2020-06-23 2022-02-23 주식회사태준제약 디쿠아포솔을 포함하는 점안 조성물
JP2023536900A (ja) 2020-08-05 2023-08-30 ティアークリアー コープ． 眼科用製剤からの防腐剤除去のためのシステムおよび方法
US12397017B2 (en) 2022-01-12 2025-08-26 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
US11951123B2 (en) 2022-01-12 2024-04-09 Platform Ophthalmic Innovations, LLC Fortified nutritional lubricating drops for dry eye disease
IT202300000006A1 (it) 2023-01-02 2024-07-02 Offhealth Spa “formulazione liposomiale di curcumina per uso oftalmico e suo metodo di preparazione industriale atto a stabilizzare nel tempo la concentrazione della stessa curcumina”
WO2025072929A1 (en) * 2023-09-28 2025-04-03 The Regents Of The University Of California Methods and compositions of treating age-related conditions

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
ATE6466T1 (de) 1979-10-26 1984-03-15 Smith And Nephew Associated Companies P.L.C. Autoklavierbare emulsionen.
JPS56104814A (en) 1980-01-25 1981-08-20 Kunihiro Okanoe Preparation of eye drop
US4649047A (en) 1985-03-19 1987-03-10 University Of Georgia Research Foundation, Inc. Ophthalmic treatment by topical administration of cyclosporin
KR920003601B1 (ko) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 점안 싸이클로스포린(cyclosporin)의 조성물
US4839342A (en) 1987-09-03 1989-06-13 University Of Georgia Research Foundation, Inc. Method of increasing tear production by topical administration of cyclosporin
BE1003578A4 (fr) 1988-10-26 1992-04-28 Sandoz Sa Nouvelles compositions ophtalmiques a base d'une cyclosporine.
IT1224795B (it) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti Uso dell'acetil d-carnitina nel trattamento terapeutico del glaucoma e composizioni farmaceutiche utili in tale trattamento
DE436726T1 (de) 1989-08-03 1992-02-06 Eisai Co., Ltd., Tokio/Tokyo Verfahren zur photostabilisierung von augenspuelloesungen sowie photostabilisierte augenspuelloesung.
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (de) 1992-09-04 1994-03-10 Basotherm Gmbh Arzneimittel zur topischen Anwendung am Auge zur Behandlung des erhöhten intraokularen Drucks
US5474979A (en) 1994-05-17 1995-12-12 Allergan, Inc. Nonirritating emulsions for sensitive tissue
EP0778021A4 (en) 1994-09-14 1998-06-03 Taisho Pharmaceutical Co Ltd DROPS TO CARE FOR THE CORNEA
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (fi) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Trimetyyliglysiinin käyttö kehon limakalvojen hygieniaan ja hoitoon tarkoitetuissa valmisteissa
AR002194A1 (es) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
US5981607A (en) 1998-01-20 1999-11-09 Allergan Emulsion eye drop for alleviation of dry eye related symptoms in dry eye patients and/or contact lens wearers
IT1302307B1 (it) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa Composizione ad attivita' antiossidante ed atta a migliorarel'utilizzazione metabolica del glucosio, comprendente acetil
AU1295200A (en) 1998-11-13 2000-06-05 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
CA2416169C (en) 2000-07-14 2008-09-23 Allergan, Inc. Compositions containing therapeutically active components having enhanced solubility
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
WO2002038161A1 (en) 2000-11-08 2002-05-16 Bio-Concept Laboratories Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
US7795203B2 (en) 2002-09-30 2010-09-14 Babizhayev Mark A Method for topical treatment of eye disease and composition and device for said treatment
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20060251685A1 (en) 2003-03-18 2006-11-09 Zhi-Jian Yu Stable ophthalmic oil-in-water emulsions with Omega-3 fatty acids for alleviating dry eye
JPWO2004084877A1 (ja) 2003-03-26 2006-06-29 株式会社メニコン 眼科用組成物
EA010437B1 (ru) * 2003-06-11 2008-08-29 Новацея, Инк. Фармацевтические композиции, содержащие активные соединения витамина d
US20050009836A1 (en) * 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
US20070265341A1 (en) 2004-07-01 2007-11-15 The Schepens Eye Research Institute Inc. Compositions and methods for treating eye disorders and conditions
BRPI0512864B8 (pt) 2004-07-01 2021-05-25 Johnson & Johnson Vision Care composição oftálmica, uso de pelo menos um ácido graxo ômega-6 e pelo menos um ácido graxo ômega-3 e método para preparar a referida composição
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7297679B2 (en) 2005-07-13 2007-11-20 Allergan, Inc. Cyclosporin compositions
US9561178B2 (en) 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
WO2008027341A2 (en) 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
CN101668511A (zh) 2007-02-28 2010-03-10 阿西克斯医疗公司 正常化睑板腺分泌的方法和化合物
JP4929245B2 (ja) 2008-07-31 2012-05-09 株式会社ベッセル工業 工具類のグリップ
EP2349232A1 (en) 2008-10-20 2011-08-03 Allergan, Inc. Ophthalmic compositions useful for improving visual acuity
IT1393419B1 (it) * 2009-03-19 2012-04-20 Medivis S R L Composizioni oftalmiche a base di acidi grassi polinsaturi omega-3 e omega-6.
US9480645B2 (en) 2009-06-02 2016-11-01 Abbott Medical Optics Inc. Omega-3 oil containing ophthalmic emulsions
US8496976B2 (en) * 2009-06-05 2013-07-30 Allergan, Inc. Artificial tears and therapeutic uses
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
KR20140103168A (ko) * 2011-12-16 2014-08-25 알러간, 인코포레이티드 폴리비닐 카프라락탐-폴리비닐 아세테이트-폴리에틸렌 글리콜 그라프트 코폴리머를 포함하는 안과 조성물
CN102934703B (zh) * 2012-11-13 2015-07-15 中国食品发酵工业研究院 一种亚麻籽油微胶囊及其生产方法

Also Published As

Publication number Publication date
EP3223794A1 (en) 2017-10-04
US20190298790A1 (en) 2019-10-03
SG11201704167PA (en) 2017-06-29
US10279005B2 (en) 2019-05-07
CL2017001301A1 (es) 2018-01-26
CN107106483B (zh) 2021-04-16
RU2697844C9 (ru) 2019-10-01
NZ732058A (en) 2023-06-30
BR112017010987A2 (pt) 2018-02-14
CN107106483A (zh) 2017-08-29
AU2015353701B2 (en) 2021-03-25
RU2017117558A3 (es) 2019-06-05
US20220143122A1 (en) 2022-05-12
IL252161B (en) 2020-09-30
JP2017535578A (ja) 2017-11-30
US20160143977A1 (en) 2016-05-26
RU2697844C2 (ru) 2019-08-21
KR102487299B1 (ko) 2023-01-10
CA2967413C (en) 2023-08-15
MX2017006474A (es) 2017-09-12
US20250228913A1 (en) 2025-07-17
WO2016085885A1 (en) 2016-06-02
CO2017005624A2 (es) 2017-10-20
RU2017117558A (ru) 2018-12-26
JP6768653B2 (ja) 2020-10-14
AU2015353701A1 (en) 2017-06-01
US20240299480A1 (en) 2024-09-12
CA2967413A1 (en) 2016-06-02
KR20170086111A (ko) 2017-07-25
MX372988B (es) 2020-04-06
UA121399C2 (uk) 2020-05-25
IL252161A0 (en) 2017-07-31
PH12017500922A1 (en) 2017-11-20

Similar Documents

Publication Publication Date Title
MX2020004076A (es) Composiciones oftalmicas estabilizadas de omega 3.
MX2020001340A (es) Modelos celulares y terapias para enfermedades oculares.
MX389460B (es) Composiciones y metodos de uso en nintedanib para tratar enfermedades oculares con neovascularizacion anormal.
CL2018001478A1 (es) Agonistas del receptor de apelina y métodos de uso
BR112019006160A2 (pt) composições e métodos para o tratamento das condições oftálmicas
ECSP19044183A (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas
MX2017014375A (es) Moduladores del ccr2.
CO2017004715A2 (es) Métodos y formulaciones para tratar enfermedades vasculares de los ojos
MX2018003388A (es) Agonistas del receptor farnesoide x y usos de los mismos.
MX2017016517A (es) Composiciones estables al almacenamiento y metodos para el tratamiento de errores de refraccion del ojo.
MX2017016655A (es) Formulaciones oftalmicas de inhibidores de tirosina quinasa, metodos de uso de las mismas y metodos de preparacion de las mismas.
CO2019004945A2 (es) Inhibidores de la magl
DK3399962T3 (da) Oftalmisk sammensætning til behandling af tør øjensygdom
CO2018004968A2 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
MX388380B (es) Composiciones para usarse en el incremento de los niveles de glóbulos rojos y el tratamiento de enfermedad de células falciformes.
AR091237A1 (es) Composiciones que comprenden un aptamero anti factor de crecimiento derivado de plaquetas (anti-pdgf) y un antagonista de factor de crecimiento de endotelio vascular (vegf)
AR096478A1 (es) Composiciones para el tratamiento de superficie que comprenden tintes fotocromáticos
DOP2018000219A (es) Anticuerpos anti-factor bb del complemento y usos de estos
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
PE20160123A1 (es) Metodos para mejorar la calidad de la composicion del meibo de las glandulas de meibomio
EA201992170A1 (ru) Модуляторы экспрессии pcsk9
MX387804B (es) Metodos para tratar presion intraocular con activadores de tie-2
SV2016005316A (es) Compuestos y composiciones para inducir condrogénesis
CO2018005393A2 (es) Anticuerpos anti-htra1 y métodos de uso de los mismos
AR100231A1 (es) Composiciones para el cuidado de las telas que comprenden polímeros de poliuretano, poliurea y/o poliuretanourea